Predictors of response to etanercept in polyarticular-course juvenile idiopathic arthritis

被引:26
作者
Geikowski, Tilman [1 ]
Becker, Ingrid [2 ]
Horneff, Gerd [1 ]
机构
[1] Asklepios Clin, Dept Pediat & Neonatol, St Augustin, Germany
[2] Univ Cologne, Inst Med Stat Informat & Epidemiol, D-50931 Cologne, Germany
关键词
juvenile idiopathic arthritis; response predictors; methotrexate; etanercept; CHILDREN; METHOTREXATE; EFFICACY; SAFETY; THERAPY;
D O I
10.1093/rheumatology/ket490
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Methods. A total of 863 patients registered in the BIKER registry were included. Predictors of response for ACR paediatric criteria (PedACR) 30, 70 and 90 were analysed by bivariate analysis and logistic regression. Results. After 6 months, 81.9% of the included patients fulfilled the PedACR30, 55.2% the PedACR70 and 31.3% the PedACR90 criteria. In bivariate analyses, factors positively correlated with a PedACR70/90 response were extended oligoarthritis JIA category, lower age at the start of treatment, shorter disease duration until treatment start, no concomitant use of corticosteroids, duration of morning stiffness, parents' global assessment of overall well-being, lower Childhood Health Assessment Questionnaire (CHAQ) and higher ESR and ANA. Correlation between the JIA category systemic arthritis and response was significantly negative. Predictive factors for PedACR70 in multivariate logistic regression analysis were CHAQ [odds ratio (OR) = 0.70], ESR (OR = 1.02) and concomitant treatment with corticosteroids (OR = 0.68). Age at treatment start (OR = 0.94) and the systemic arthritis JIA category (OR = 0.28) were predictive for a PedACR70. We found no sufficiently distinctive models for PedACR30 or 90. Conclusion. Parameters predicting a high-grade response to a 6-month course of etanercept were identifiable and included age at treatment start, disease duration before treatment, JIA category other than systemic arthritis, CHAQ, parents' global assessment and concomitant corticosteroids.
引用
收藏
页码:1245 / 1249
页数:5
相关论文
共 16 条
[1]
The magnitude of early response to methotrexate therapy predicts long-term outcome of patients with juvenile idiopathic arthritis [J].
Bartoli, M. ;
Taro, M. ;
Magni-Manzoni, S. ;
Pistorio, A. ;
Traverso, F. ;
Viola, S. ;
Magnani, A. ;
Gasparini, C. ;
Martini, A. ;
Ravelli, A. .
ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (03) :370-374
[2]
METHOTREXATE IN RESISTANT JUVENILE RHEUMATOID-ARTHRITIS - RESULTS OF THE USA-USSR DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL [J].
GIANNINI, EH ;
BREWER, EJ ;
KUZMINA, N ;
SHAIKOV, A ;
MAXIMOV, A ;
VORONTSOV, I ;
FINK, CW ;
NEWMAN, AJ ;
CASSIDY, JT ;
ZEMEL, LS .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (16) :1043-1049
[3]
The German etanercept registry for treatment of juvenile idiopathic arthritis [J].
Horneff, G ;
Schmeling, H ;
Biedermann, T ;
Foeldvari, I ;
Ganser, G ;
Girschick, HJ ;
Hospach, T ;
Huppertz, HI ;
Keitzer, R ;
Küster, RM ;
Michels, H ;
Moebius, D ;
Rogalski, B ;
Thon, A .
ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 (12) :1638-1644
[4]
Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry [J].
Horneff, G. ;
De Bock, F. ;
Foeldvari, I. ;
Girschick, H. J. ;
Michels, H. ;
Moebius, D. ;
Schmeling, H. .
ANNALS OF THE RHEUMATIC DISEASES, 2009, 68 (04) :519-525
[5]
Report on malignancies in the German juvenile idiopathic arthritis registry [J].
Horneff, Gerd ;
Foeldvari, Ivan ;
Minden, Kirsten ;
Moebius, Dagmar ;
Hospach, Toni .
RHEUMATOLOGY, 2011, 50 (01) :230-236
[6]
Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis [J].
Lovell, Daniel J. ;
Reiff, Andreas ;
Ilowite, Norman T. ;
Wallace, Carol A. ;
Chon, Yun ;
Lin, Shao-Lee ;
Baumgartner, Scott W. ;
Giannini, Edward H. .
ARTHRITIS AND RHEUMATISM, 2008, 58 (05) :1496-1504
[7]
Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis [J].
Lovell, DJ ;
Reiff, A ;
Jones, OY ;
Schneider, R ;
Nocton, J ;
Stein, LD ;
Gedalia, A ;
Ilowite, NT ;
Wallace, CA ;
Whitmore, JB ;
White, B ;
Giannini, EH .
ARTHRITIS AND RHEUMATISM, 2006, 54 (06) :1987-1994
[8]
Etanercept in children with polyarticular juvenile rheumatoid arthritis. [J].
Lovell, DJ ;
Giannini, EH ;
Reiff, A ;
Cawkwell, GD ;
Silverman, ED ;
Nocton, JJ ;
Stein, LD ;
Gedalia, A ;
Ilowite, NT ;
Wallace, CA ;
Whitmore, J ;
Finck, BK .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (11) :763-769
[9]
Minden K, 2008, Z RHEUMATOL, V67, P100, DOI 10.1007/s00393-007-0246-5
[10]
Factors Associated With Treatment Response to Etanercept in Juvenile Idiopathic Arthritis [J].
Otten, Marieke H. ;
Prince, Femke H. M. ;
Armbrust, Wineke ;
ten Cate, Rebecca ;
Hoppenreijs, Esther P. A. H. ;
Twilt, Marinka ;
Koopman-Keemink, Yvonne ;
Gorter, Simone L. ;
Dolman, Koert M. ;
Swart, Joost F. ;
van den Berg, J. Merlijn ;
Wulffraat, Nico M. ;
van Rossum, Marion A. J. ;
van Suijlekom-Smit, Lisette W. A. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2011, 306 (21) :2340-2347